NCT02924337 is a Phase 1 clinical trial of Imeglimin in Qt Interval, Variation in, sponsored by Poxel SA.

Who is sponsoring NCT02924337?

NCT02924337 is sponsored by Poxel SA.

What drugs are being tested in NCT02924337?

Interventions in NCT02924337: Placebo, Imeglimin, Moxifloxacin.

What condition does NCT02924337 study?

NCT02924337 studies Qt Interval, Variation in.

Is NCT02924337 still recruiting?

NCT02924337 is currently completed. Last updated 9 February 2017.

Last reviewed 2017-02-09 · How we verify

NCT02924337

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised, Double-blind, Placebo and Active Controlled Crossover Study to Assess the Effect of Single Dose Administration of 2 Doses of Imeglimin on QT/QTc Intervals in Healthy Subjects

Completed Phase 1 Last updated 9 February 2017

What this trial tests

Phase 1 trial testing Placebo in Qt Interval, Variation in in 55 participants. Completed in 1 December 2016.

Timeline

1 September 2016

Primary endpoint
1 December 2016

1 December 2016

Quick facts

Lead sponsor	Poxel SA
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	55
Start date	1 September 2016
Primary completion	1 December 2016
Estimated completion	1 December 2016
Sites	1 location across United Kingdom

Drugs / interventions tested

Placebo
Imeglimin (IMEGLIMIN) — full drug profile →
Moxifloxacin (moxifloxacin) — full drug profile →

Conditions studied

Qt Interval, Variation in — all drugs for Qt Interval, Variation in →

Sponsor

Poxel SA — full company profile →

Who can join

Adults 18 to 45, any sex, with Qt Interval, Variation in. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in QTcF (deltaQTcF)
Time frame: Up to 24 hours

Sponsor's own description

The purpose of this study is to assess the effect of a single therapeutic dose and a single supra-therapeutic dose of imeglimin on the QT/QTc interval

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, et al · · 2020 · cited 11× · PMID 32556539 · DOI 10.1007/s00228-020-02929-6

Verify or expand the search:

Other trials of Imeglimin

Trials testing the same drug.

NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT05366868 — Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus · Phase 4 · active not recruiting
NCT03802786 — Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects · Phase 1 · completed
NCT03646331 — Bioequivalence of Imeglimin Tablet Formulations · Phase 1 · completed
NCT03618316 — Effect of Cimetidine on the PK of Imeglimin · Phase 1 · completed

Other Poxel SA trials

Trials by the same sponsor.

NCT05441904 — Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. · Phase 1 · completed
NCT04321343 — Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) · Phase 2 · completed
NCT03950882 — A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD · Phase 1 · completed
NCT03763877 — A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD · Phase 2 · completed
NCT03886103 — Pharmacokinetics and Metabolism of (14C)-Labelled PXL770 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02924337 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poxel SA
Last refreshed: 9 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02924337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing